feed,title,long_url,short_url
Benzinga,Monthly Dosing Of Sarepta's Next-Gen Eteplirsen Can Potentially Achieve Over 10% Higher Dystrophin Expression In DMD Patients,https://benzinga.com/general/biotech/21/05/20917852/monthly-dosing-of-sareptas-next-gen-eteplirsen-can-potentially-achieve-over-10-higher-dystrophin-,https://j.mp/2PITilS
